![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 09, 2019 4:46:15 PM
Today's price action, which surprised me, dropped the price to an intraday low of $3.25.I see this as shaking out the weak hands and healthy for continued long term stock price appreciation.
The RMS strategy of developing partnerships with big pharma is starting to bare fruit. The sales of Grifols/Xemblify's subQ formulation commences in Q4. Approval outside of the U.S should follow. This revenue stream will ramp up beginning 2020.
The migration to home infusion for cost and convenience reasons will encourage drug makers to reconfigure drug formulation so they can be administered at home via SubQ.
RMS received another favorable ruling against EDEM in NY.(This is the second favorable ruling. The first was in TX.) The NY suit was the most expensive of the suits and this will save a lot of legal expenses. With two strikes against EDEM the incentive for settlement grows.
The RMS story remains largely untold. Uplisting to a major exchange expected and will bring additional buyers and coverage. Possibly becoming part of a Russell indexed fund down the line.
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM